Search
Search Results
-
-
Cytokine levels in patients with non-M3 myeloid leukemia are key indicators of how well the disease responds to chemotherapy
Acute myeloid leukemia (AML) is a malignant hematological neoplastic disease. Autocrine or paracrine cytokines released by leukemic cells regulate...
-
Mast Cell Activation Syndrome: A Primer for the Gastroenterologist
Mast cell activation syndrome is thought to be a common, yet under-recognized, chronic multi-system disorder caused by inappropriate mast cell...
-
Tespa1 facilitates hematopoietic and leukemic stem cell maintenance by restricting c-Myc degradation
Hematopoietic stem cells (HSCs) and leukemia stem cells (LSCs) have robust self-renewal potential, which is responsible for sustaining normal and...
-
Identification of a leukemia-initiating stem cell in human mast cell leukemia
Mast cell leukemia (MCL) is a highly fatal malignancy characterized by devastating expansion of immature mast cells in various organs. Although...
-
l-Asparaginase as the gold standard in the treatment of acute lymphoblastic leukemia: a comprehensive review
l -Asparaginase is an antileukemic drug long approved for clinical use to treat childhood acute lymphoblastic leukemia, the most common cancer in this...
-
Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG)
Clinical outcome of patients with acute myeloid leukemia (AML) is associated with demographic and genetic features. Although the associations of...
-
Immune Metabolism in TH2 Responses: New Opportunities to Improve Allergy Treatment — Cell Type-Specific Findings (Part 2)
Purpose of ReviewOver the last years, we have learned that the metabolic phenotype of immune cells is closely connected to the cell’s effector...
-
Siglec-6 is a target for chimeric antigen receptor T-cell treatment of chronic lymphocytic leukemia
The only current curative treatment for chronic lymphocytic leukemia (CLL) is allogenic hematopoietic stem cell transplantation. Chimeric antigen...
-
New Treatment Options for Newly-Diagnosed and Relapsed Chronic Lymphocytic Leukemia
The better understanding of the biology of chronic lymphocytic leukemia (CLL) gained over the past decade has led to the development and introduction...
-
CD72, a new immune checkpoint molecule, is a novel prognostic biomarker for kidney renal clear cell carcinoma
BackgroundThe incidence and mortality of clear cell carcinoma of the kidney increases yearly. There are limited screening methods and advances in...
-
Atopy manifestations in pediatric patients with acute lymphoblastic leukemia: correlation assessment with interleukin-4 (IL-4) and IgE level
BackgroundAcute lymphoblastic leukemia (ALL) is the most common type of cancer in the age range of under 15 years old and accounts for 25–30% of all...
-
Laboratory Evaluation and Pathological Workup of Neoplastic Monocytosis — Chronic Myelomonocytic Leukemia and Beyond
Purpose of ReviewMonocytosis is a distinct but non-specific manifestation of various physiologic and pathologic conditions. Among hematopoietic stem...
-
15 years Ludwig Boltzmann Institute for Hematology and Oncology (LBI HO): achievements and future perspectives
Cancer stem cells, also known as leukemic stem cells (LSC) in the context of leukemias, are an emerging topic in translational oncology and...
-
Comprehensive analysis of immune cell landscapes revealed that immune cell ratio eosinophil/B.cell.memory is predictive of survival in sepsis
BackgroundImmune dysregulation is a feature of sepsis. However, a comprehensive analysis of the immune landscapes in septic patients has not been...
-
Pathologic characteristics of histiocytic and dendritic cell neoplasms
Histiocytic and dendritic cell neoplasms comprise diverse tumors originating from the mononuclear phagocytic system, which includes monocytes,...
-
Immunophenotypic challenges in diagnosis of CD79a negativity in a patient with B acute lymphoblastic leukemia harboring intrachromosomal amplification of chromosome 21: a case report
BackgroundBeing expressed in all stages of B-cell development and having a significant value on the European Group for the Immunological...
-
“Off-the-Shelf” Allogeneic CAR Cell Therapy—Neglected HvG Effect
Chimeric antigen receptor (CAR) cell therapy offers patients with hematological malignancies a new therapeutic option. Traditionally, autologous T...
-
A single-cell survey of cellular hierarchy in acute myeloid leukemia
BackgroundAcute myeloid leukemia (AML) is a fatal hematopoietic malignancy and has a prognosis that varies with its genetic complexity. However,...
-
Mast cell activation in the context of elevated basal serum tryptase: genetics and presentations
Purpose of ReviewTo describe inherited and acquired genetic variants and clinical entities associated with increased basal serum tryptase (BST),...
